SEHK:9926Biotechs
Akeso (SEHK:9926) Valuation Check After New HARMONi-2 Quality Of Life And Survival Data
Akeso (SEHK:9926) is back in focus after new HARMONi-2 data at the 2026 European Lung Cancer Congress showed its PD-1/VEGF antibody ivonescimab improved both progression-free survival and health-related quality of life versus pembrolizumab.
See our latest analysis for Akeso.
The new HARMONi-2 data and recent China approvals are landing alongside strong momentum, with a 30-day share price return of 30.94% and a 1-year total shareholder return of 63.56%, pointing to rising investor risk...